DERMABOND PRINEO Skin Closure System

DERMABOND PRINEO Skin Closure System provides a flexible microbial barrier with 99% protection in vitro for 72 hours against organisms commonly responsible for SSIs.1,* DERMABOND PRINEO Skin Closure System was shown to provide statistically significant greater skin holding strength than skin staples or subcuticular 4-0 MONOCRYL (poliglecaprone 25) suture.2,**

DERMABOND® PRINEO® Skin Closure System

Supporting Documentation

Product Support

DERMABOND PRINEO Skin Closure System 22cm One-Pager

DERMABOND PRINEO Skin Closure System (22cm) ODP Quick Guide

Value Analysis Brief for DERMABOND PRINEO Skin Closure System

DERMABOND PRINEO Skin Closure System Discussion Guide

References

* Staphylococcus epidermidis, Escherichia coli,  Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecium.

** In an ex-vivo study, more load in N was required to create a 3 ±1 mm gap between skin edges approximated with DERMABOND PRINEO System, than with subcuticular 4-0 MONOCRYL Suture or PROXIMATE ETHICON ENDO SURGERY skin staples (p=0.00).

1. Ethicon, Su 06TR071 Study Report for in vitro evaluation of microbial barrier properties of DERMABOND ProTape, December 2006, Data on File.

2. Ethicon, AST-2012-0290: Study to Compare the tissue holding strength of PRINEO skin closure system with conventional wound closure techniques, October 2012, Data on File. 

© Johnson & Johnson Medical N.V., Belgium 2017.